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Daiki Kobayashi*, Osamu Takahashi, Hiroko Arioka and Tsuguya FukuiAbstract
Background: Gastric cancer is one of the most significant diseases, and esophago-gastro-duodenoscopy (EGD) is
one of screening methods for gastric cancer. This study was conducted to identify the optimal screening interval
for gastric cancer using EGD in healthy adults.
Methods: A retrospective cohort study was conducted on 3,723 healthy participants without a known diagnosis of
gastric cancer at baseline from January 2005 to December 2010. Participants underwent annual health screenings,
including EGD, at the Center for Preventive Medicine at St Luke’s International Hospital, a community teaching
hospital in Japan. Participants with cytological abnormalities underwent further examination. A generalized
estimating equation (GEE) was used to analyze the longitudinal data. We decided 0.5% of incidence of gastric
cancer as a cutoff point for interval.
Results: The mean age (SD) of the participants was 55 (11) years, and 1,879 (50.5%) were male. During the study
period, gastric cancer was detected in 35 participants. However, the incidence varied based on their ages. In the
age groups <40, 40–49, 50–59, 60–69 and ≥70 years old, the 5-year cumulative incidences (95%CI) of gastric cancer
were 0% (0-0%), 0.3% (0.1-1.0%), 1.0% (0.5-1.8%), 1.4% (0.8-2.4%) and 1.9% (0.8-3.8%), respectively. The odds ratios of
the incidence of gastric cancer per year, which were evaluated using GEE models for the age groups 40–49, 50–59,
60–69 and ≥70 years old, were 1.51 (95%CI: 0.91-2.49), 1.94 (95%CI: 1.31-2.86), 1.59 (95%CI: 1.23-2.06) and 1.46 (95%
CI: 1.06-2.02), respectively.
Conclusions: A screening for gastric cancer using EGD may be appropriate annually for healthy people over 70
years old, every two or three years for people 60–69 years old and every four years for people 50–59 years old.
People younger than 50 years old may only need repeat screenings every five years or more.Background
Approximately 776,000 patients die from gastric cancer
worldwide each year [1]. Japan has one of the highest
rates of gastric cancer in the world; approximately
50,000 patients in Japan die from gastric cancer each
year [2].
Some countries with high incidences of gastric cancer,
including Japan [3], Chile [4] and Venezuela [5], recom-
mend mass screening for gastric cancer, while other
countries do not recommend routine screening [6]. In
these high risk countries, mass screening for gastric can-
cer is expected to increase the early detection rate and
reduce the mortality from gastric cancer based on previ-
ous large-scale case control studies and reviews [7,8].* Correspondence: daikoba@luke.or.jp
Division of General Internal Medicine, Department of Internal Medicine, St.
Luke’s International Hospital, Tokyo, Japan
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reproduction in any medium, provided the orScreening strategies for gastric cancer, however, are
different among these high incidence countries.
Esophago-gastro-duodenoscopy (EGD) is a screening
method that is readily available and recommended by
some experts in Japan [9]. Although there is a systematic
review which recommends barium x-ray [10], the sensi-
tivity of barium x-rays is lower than that of EGD. Con-
sidering the fact that approximately 40% of gastric
cancers are still undetected [11], higher sensitivity of
screening method is of paramount importance. More-
over, the incidence of complications during EGDs was
reported as low as 0.012% and the mortality rate was
only 0.001% in Japan [12]. Finally, EGD was shown to be
cost effective in a systematic review [13].
However, the optimal interval of EGD screening for
gastric cancer is yet to be determined. Therefore, weral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cer screening using a 5-year cohort.
Methods
Study participants
From January 2005 to December 2010, all participants
(≥20 years old) who underwent EGD as a part of an an-
nual health check-up program at the Center for Prevent-
ive Medicine at St. Luke’s International Hospital in
Tokyo, Japan, were enrolled in this cohort study. We
included all participants who have completed 5 years fol-
low up. We also included patients who were found gas-
tric cancer during study period, even if they have not
completed the remaining years. We excluded people
with a diagnosis of gastric cancer at baseline. Previous
EGD was not restricted in our study.
Data collection
We extracted data from the electronic health records of
participants who had annual health screenings in 2005
(baseline year), 2006 (year 1), 2007 (year 2), 2008 (year
3), 2009 (year 4) and 2010 (year 5). The participants
diagnosed with gastric cancer based on cytology were
further evaluated at the Department of Gastroentero-
logical Medicine or Digestive Surgery at St. Luke’s Inter-
national Hospital. The cytology was evaluated by two
pathologists independently. We aggregated informationTable 1 Participant characteristics
Gastric cancer patients
over five years (n=35)
Age, mean (SD) years 62 (9)
Gender, male (%) n 25 (71.4)
BMI, mean (SD) kg/m [2] 23.8 (3.1)
SBP mean (SD), mmHg 125.4 (13.6)
DBP mean (SD), mmHg 77.1 (7.9)
Heart rate mean (SD), bpm 69.5 (9.4)
White blood cell mean (SD), *10 [3] /μl 5.6 (1.5)
Hemoglobin mean (SD), g/dl 14.1 (1.0)
Platelet mean (SD), *10 [6] /μl 224.2 (43.5)
Fasting blood sugar mean (SD), mg/dl 108.3 (18.8)
HgbA1c mean (SD), % 5.3 (0.7)
LDL-cho mean (SD), mg/dl 117.0 (21.8)
HDL-cho mean (SD), mg/dl 58.2 (12.8)
TG mean (SD), mg/dl 107.4 (53.0)
Family history of gastric cancer n (%) 8 (1.2)
Alcohol habit n (%) 24 (68.6)
Smoker: Brinckman index n (SD) 430.7 (648.0)
Salt intake: g per day g (SD) 12.7 (3.4)
Gastric ulcer n (%) 3 (1.2)
Number of cigarettes smoked per day times the number of smoking years.from the participants who were determined to have gas-
tric cancer by cytology and were evaluated at the other
hospitals. The St. Luke’s International Hospital’s ethics
committee approved the protocol for this study.
Measurements
The annual health check-up program contained an ini-
tial evaluation during which demographic and medical
history information was collected. An EGD was per-
formed by a gastroenterological specialist, and the cyto-
logical specimens were evaluated by two independent
pathologists. Participants were divided into four age
brackets: under 40 years of age, 40–49 years, 50–59
years, 60–69 years and 70 years or older. The incidence
of gastric cancer, the odds ratio of the incidence over
five years and the proportion of gastric cancers to the
number of biopsies were used as indicators to define the
optimal intervals for screening. An incidence of 0.5% for
gastric cancer was considered the cutoff point based on
a previous interval study and the Japanese prevalence of
gastric cancer [14].
Statistical methods
Data were analyzed using descriptive statistics, including
the mean, variance, standard deviation (SD), and per-
centage. Chi-squared and Fisher’s exact tests were used






55 (12) 55 (12) <0.01
1,854 (50.3) 1,879 (50.5) <0.01
22.5 (3.1) 22.5 (3.1) 0.01
120.7(18.2) 120.8 (18.2) 0.05
74.9 (11.3) 75.0 (11.3) 0.12
73.4 (11.3) 73.3 (11.3) 0.04
5.1 (1.4) 5.1 (1.4) 0.06
13.9 (1.3) 13.9 (1.3) 0.21
234.4 (51.0) 234.3 (51.0) 0.24
101.5 (17.2) 101.6 (17.3) 0.39
5.2 (0.6) 5.2 (0.6) 0.27
120.5 (29.0) 120.5 (29.0) 0.47
62.8 (15.7) 62.7 (15.7) 0.08
102.8 (70.7) 102.8 (70.5) 0.70
677 (18.4) 685 (18.4) 0.31
2,157 (58.5) 2,181 (58.6) 0.15
210.6 (412.7) 21.7 (415.9) 0.05
12.2 (3.8) 12.2 (3.8) 0.44
239 (6.5) 242 (6.5) 0.40
Figure 1 The cumulative incidence of gastric cancer for 5 years by age group.
Kobayashi et al. BMC Gastroenterology 2012, 12:144 Page 3 of 6
http://www.biomedcentral.com/1471-230X/12/144Additionally, generalized estimating equations (GEE)
[15], which were adjusted for possible risk factors, such
as age, gender, alcohol consumption, smoking, family
history, past medical history of gastric ulcers, salt intake
and body mass index (BMI) [16-19], were used to evalu-
ate the odds ratio of the cumulative incidence of gastric
cancer [20]. GEE is performed to estimate the para-
meters of a generalized linear model with a possible un-
known correlation between outcomes [21]. With this
analysis, we can estimate likelihood with considering
correlation matrix for the vector of repeated observa-
tions from each subject [22].
The majority of the data analyses were performed
using the SPSS software 15.0J (SPSS Japan, Tokyo,
Japan), except for the 95% confidence intervals (CI)
based on an exact binominal [23] and the GEE methods
which were calculated using the Stata version 10
(STATA Corp., College Station, TX, USA).
Results
From January 2005 to December 2010, 3,723 participants
completed all five yearly health screenings. The mean age
(SD) of participants was 55 (12) years, and 1,879 partici-
pants (50.5%) were male. The mean (SD) body mass index
(BMI) was 22.5 (3.1) kg/m [2]. Of the participants, 685Table 2 Types of gastric cancer
<40 40-49 50-59 60-69 ≥70 Total
Adenocarcinoma 0 0 7 11 6 24
MALT* lymphoma 0 0 3 2 1 6
Signet cell carcinoma 0 3 1 0 0 4
Carcinoid 0 0 1 0 0 1
Total 0 3 12 13 7 35
MALT*: Mucosa-associated lymphoid tissue.(18.4) had a family history of gastric cancer, and 242 (6.5)
had a past medical history of gastric cancer. Other base-
line characteristics are shown in Table 1.
After 5 years, the cumulative incidence of gastric can-
cer was 0.9% (95% CI, 0.7-1.3). However, the incidence
varied greatly between age groups. At 5 years, the parti-
cipants who were <40, 40–49, 50–59, 60–69 and ≥70
years old at baseline had cumulative incidences (95% CI)
of gastric cancer of 0% (0-0%), 0.3% (0.1-1.0%), 1.0%
(0.5-1.8%), 1.4% (0.8-2.4%) and 1.9% (0.8-3.8%), respect-
ively (Figure 1).
During this 5 years period, 964 biopsies were per-
formed, and 35 patients (3.6%, 95%CI: 2.5%-5.0%) were
diagnosed with gastric cancer. All of them were followed
throughout the study period (100%). Of these patients,
24 had adenocarcinoma, 6 had mucosa-associated
lymphoid tissue (MALT) lymphoma, 4 had signet cell
carcinoma, and 1 had carcinoid (Table 2). Among 24
patients with adenocarcinoma, 20 were able to be fol-
lowed up with their stage of cancer. 17 patients were
Stage IA, and 3 patients were Stage IB.
The patients with MALT lymphoma were treated by
eradicating of H. pylori. Among other patients, 20 were
determined to have cancer at an early stage and were
treated with endoscopic submucosal dissection (ESD),
and 9 underwent gastrectomy (Table 3).
Table 4 shows the ratio of the incidence of gastric can-
cer per the number of biopsies. At 5 years, the partici-
pants who were <40, 40–49, 50–59, 60–69 and ≥70
years old at baseline had ratios (95% CI) of 0% (0-0%),
1.9% (0.4-5.4%), 3.5% (1.8-6.0%), 4.5% (2.4-7.6%) and
4.8% (2.0-9.7%), respectively. The ratio (95% CI) for all
participants was 3.6 (2.5-5.0%).
The odds ratios for the incidence of gastric cancer per
year were estimated using GEE models adjusted for possible
Table 3 Types of treatment for gastric cancer
<40 40-49 50-59 60-69 ≥70 Total
ESD* 0 1 4 11 4 20
Gastrectomy 0 2 5 0 2 9
H. pylori eradication 0 0 3 2 1 6
Total 0 3 12 13 7 35
ESD*: Endoscopic submucosal dissection.
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smoking, family history, past medical history of gastric
ulcers, salt intake and BMI. The independent odds ratios
for the incidence of gastric cancer in the 40–49, 50–59, 60–
69 and ≥70 years old age groups were 1.51 (95%CI: 0.91-
2.49), 1.94 (95%CI: 1.31-2.86), 1.59 (95%CI: 1.23-2.06) and
1.46 (95%CI: 1.06-2.02), respectively. None of the partici-
pants who were <40 years old had gastric cancer. (Table 5)
Although there was no statistical relationship between gas-
tric cancer and other variables, high BMI tended to be asso-
ciated with high incidence of gastric cancer.Discussion
This study showed that the incidence rates of gastric
cancer significantly differed according to age. Accord-
ingly, our recommended screening intervals were based
on age brackets. For patients over 70 years old, screening
for gastric cancer every year may be appropriate, and for
patients 60–69 years old, every two or three years, for
patients 50–59 years old, every three or four years, and
for patients 40–49 years old and under 40 years old,
every five years.
In the group of participants older than 70 years old,
approximately 0.5% developed gastric cancer within the
next year. The proportion of the incidence of gastric
cancer to the number of biopsies was 7 / 145 (4.8%)
compared to 35 / 964 (3.6%) in all participants. Having
adjusted for multiple variables using GEE model, the
odds ratio for the incidences of gastric cancer within the
next year turned to be 1.46 (95%CI: 1.06-2.02). Cancer
screening tends to be controversial in elderly people be-
cause of their remaining life expectancy. However, in
Japan, the life expectancy is 80 years old for males andTable 4 Positive biopsy ratio for gastric cancer over 5 years
<40 40-49 50-59
2006 0 / 4 0 / 27 0 / 5
2007 0 / 9 1 / 32 3 / 7
2008 0 / 4 1 / 35 1 / 7
2009 0 / 4 1 / 18 2 / 6
2010 0 / 6 0 /47 6 / 7
Total (%) 0 / 27 (0) 3 / 159 (1.9) 12 / 344 (3.5
Incidence of gastric cancer / number of biopsies.86 years old for females [24], long enough for justifying
cancer screening for people aged over 70 years.
For the 60–69 year-old age group, the incidence of
gastric cancer exceeded 0.5% within the next three years.
The proportion of the incidence of gastric cancer to the
number of biopsies was 13 / 289 (4.5%), and the propor-
tion was higher than for gastric cancer in all partici-
pants. In the GEE model, the odds ratio for the
incidence of gastric cancer within the next year was 1.59
(95%CI: 1.23-2.06). Therefore, screening every two or
three years may be appropriate.
For patients 50–59 years old, the incidence of gastric
cancer was approximately 0.5% within the next four
years. The proportion of the incidence of gastric cancer
to the number of biopsies was 12 / 344 (3.5%), similar to
the proportion of gastric cancer in all participants. Based
on the GEE model, the odds ratio for the incidence of
gastric cancer within the next year was 1.94 (95%CI:
1.31-2.86), and it was the highest among all the groups.
Therefore, screening every four years may be reasonable.
For patients 40–49 years old, the incidence of gastric
cancer was less than 0.5% within the next five years. The
proportion of the incidence of gastric cancer to the
number of biopsies was 3 / 159 (1.9%), and the propor-
tion was lower than that for all participants. Based on
the GEE model, the odds ratio for the incidence of gas-
tric cancer in the next year was 1.51 (95%CI: 0.91-2.49),
which attained no statistically significance. Therefore,
screening every five or more years may be considered.
However, in this group, all patients with gastric cancer
had signet cell carcinoma, which has poor prognosis.
This means that screening patients in this group may
have to be considered carefully.
Among those under 40 years old, there were no patients
with gastric cancer. Therefore, screening every five or
more years may be appropriate for this age bracket.
In our study, 20 of 29 (69.0%, 95%CI: 49.2-84.7) patients
with gastric cancer (excluding MALT lymphoma because
of the differences in treatment) were detected in the early
stage and treated with ESD. Compared to a previous study
on barium x-ray screening program, the early stage detec-
tion rate in our study was high [25]. It is speculated that
early detection of gastric cancer by nation which screening60-69 ≥70 Total
5 2 / 57 2 / 18 4 / 161
6 2 / 62 1 / 34 7 / 213
0 2 / 53 2 / 26 6 / 188
4 4 /67 2 / 35 9 / 188
9 3 /50 0 / 32 9 / 214
) 13 / 289 (4.5) 7 / 145 (4.8) 35 / 964 (3.6)
Table 5 Odds ratios for the incidences of gastric cancer per year using a generalized estimating equation (GEE) in each
age group, adjusted for age, gender, alcohol consumption, smoking, family history, past medical history of gastric
ulcers, salt intake and body mass index (BMI)
Age Odds Ratio 95% Confidence Interval Standard Deviation p-value
<40 No incidence
40-49 1.51 0.91 - 2.49 0.36 0.11
50-59 1.94 1.31 – 2.86 0.38 <0.01
60-69 1.59 1.23 – 2.06 0.21 <0.01
≥70 1.46 1.06 – 2.02 0.24 0.02
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from gastric cancer in the past decades [7]. In this regard,
gastric cancer screening using EGD which detects gastric
cancer in earlier stage than barium X-ray may be efficient.
In addition to that, early detection for gastric cancer
was expected better prognosis than late detection. Previ-
ous study reported that the five years survival rate with
gastric cancer in Stage I, II, III, IV were 99.1%, 72.6%,
45.9%, and 7.2% respectively in Japan [26]. Among 24
patients with adenocarcinoma, at least 20 patients were
in Stage IA or IB in our study. Within them, 16 patients
were treated by ESD, which was less invasive than gas-
trectomy. Therefore, patients in our study were expected
not only early detection for gastric cancer, but also bet-
ter prognosis.
There are some limitations to this study. First, this study
was a retrospective cohort study. We could not determine
the magnitude of false negative results. There is a report,
however, which reported that the false negative rate for gas-
tric cancer screening by EGD was nil while 12 months
follow-up [27]. Therefore, we would think the effect of false
negatives negligible in our study. Second, our data did not
include information on H. pylori. It is said that 70-80% of
people over 40 years old in Japan had H. pylori [28]. A pre-
vious randomized controlled study showed that H. pylori
eradication reduced precancerous lesions without affecting
overall incidence of gastric cancer [29]. For this reason, the
information on H. pylori infection is unlikely to affect our
results from 5 years cohort study. Third, population in our
study may have selection bias, because of the study design.
However, the incidence of gastric cancer in our study was
similar to that in the previous study in Japan [30]. There-
fore, this is also unlikely to affect the result. Finally, our data
didn’t have the information of atrophic gastritis. Previous
study revealed that atrophic gastritis may be a major cause
of gastric cancer [31]. For these reasons, additional studies
are required to further evaluation.
Conclusions
A screening program for gastric cancer may be appropri-
ate every year for healthy people over 70 years old, every
two or three years for those 60–69 years old and every
four years for those 50–59 years old. People youngerthan 50 years old may only need screenings every five
years or more.
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